MAPT and Alzheimer disease: Whereas in the previous version of the framework (Jack et al., 2016), an isolated positive beta-Amyloid (A+) biomarker status was sufficient for AD classification, in the latest version (Jack et al., 2018), having both a beta-Amyloid (A+) and phospho-Tau (T+) biomarker status is required for an AD classification.